US Stock Market Move | Weight-loss drug data success ignites stock price, Viking Therapeutics (VKTX.US) soars over 30%.

On Tuesday, Viking Therapeutics (VKTX.US) opened higher and continued to climb, surging over 30% as of press time. On the news front, the biotech company announced that its experimental obesity drug VK2735 helped patients maintain most of their weight loss results even when the dosing frequency was reduced from once weekly to once every two weeks. This result could further strengthen VK2735's competitive position in the rapidly expanding weight-loss drug market. VK2735 is seen as a potential competitor to blockbuster weight-loss drugs such as Eli Lilly's Zepbound and Novo Nordisk A/S Sponsored ADR Class B Wegovy.